It is known that the abnormal activation of Akt‐GSK3β signalling pathway increases proliferation rate of T lymphocytes of SLE patients.28 Enhanced activity of the PI3K signalling pathway with up‐regulation of phosphorylated Akt (pAkt) in T cells is also described in mouse models.29 We extended the investigation of the Erk and Akt pathways in hiPSCs‐SLE, by further characterizing these signalling pathways, with the aim to uncover new potential therapeutic targets. This evidence concerns the gene AKT1 and systemic lupus erythematosus.